Drechsler HJ, Gerber MT, Laffey EA, Sarlone C, Amyot KC, Aberg JA; International Conference on AIDS (15th : 2004 : Bangkok, Thailand).

Int Conf AIDS. 2004 Jul 11-16; 15: abstract no. MoPeB3169.

Washington University School of Medicine, St. Louis MO, United States

Background: Screening for G6PD deficiency has traditionally focused on males, as G6PD is an X-linked trait. Published reports of G6PD deficiency prevalence range from 5.7% to 13.7% of black males. The prevalence rates in females and non-black populations have not been described in the US. The rationale to screen for G6PD deficiency in HIV-infected individuals is their potential to receive oxidative drugs such as dapsone or primaquine, but current guidelines as to whom should be screened are conflicting. Methods: We reviewed 1739 medical records in an urban HIV clinic for G6PD levels, hemolytic events, and dapsone or primaquine use during a 7-year period. We also identified G6PD levels based on race and gender in a cohort of 526 US Air Force personnel. Results: In the military cohort, 4/31 (12.9%) black females, 6/52 (11.5%) black males, 0/80 white females, and 1/316 (0.3%) white males were G6PD deficient. In our HIV clinic 16% of the patients were screened for G6PD deficiency in a 7-year period. 8/77 (10%) black females, 20/135 (14.8%) black men, 0/16 white females, and 3/52 (5.8%) white men were G6PD deficient. 222/1739 (13%) patients received either dapsone or primaquine. 8 drug related hemolytic events were identified (5 dapsone, 1 primaquine, 2 TMP/SMX), 2 of which resulted in blood transfusions. Of these only 2/6 patients screened were G6PD deficient. Conclusions: Sex and gender based prevalence rates of G6PD deficiency in the HIV-infected population were similar to those in a military cohort and are thus likely reflective of the general population. We found no cases of G6PD deficiency in white women. While G6PD deficiency frequently occurs in both in black men and women, its clinical significance in our HIV-infected patients was low. In contrast to some guidelines, targeted screening based on race, gender, and medication use would likely be more cost-effective.

Publication Types:

• Meeting Abstracts

Keywords:

• AIDS Vaccines
• Acquired Immunodeficiency Syndrome
• African Americans
• African Continental Ancestry Group
• Continental Population Groups
• European Continental Ancestry Group
• Female
• Glucosephosphate Dehydrogenase
• Glucosephosphate Dehydrogenase Deficiency
• HIV Infections
• HIV Seropositivity
• Humans
• Male
• Mass Screening
• Prevalence

Other ID:

• GWAIDS0035257

UI: 102279473

From Meeting Abstracts